M
Mike Waterfield
Researcher at Ludwig Institute for Cancer Research
Publications - 67
Citations - 9392
Mike Waterfield is an academic researcher from Ludwig Institute for Cancer Research. The author has contributed to research in topics: Epidermal growth factor & Kinase. The author has an hindex of 41, co-authored 67 publications receiving 9277 citations. Previous affiliations of Mike Waterfield include University College London.
Papers
More filters
Journal ArticleDOI
Close similarity of epidermal growth factor receptor and v- erb-B oncogene protein sequences
Julian Downward,Yosef Yarden,E. Mayes,G. Scrace,Nick Totty,P. Stockwell,Axel Ullrich,Joseph Schlessinger,Mike Waterfield +8 more
TL;DR: Six peptides derived from the human epidermal growth factor receptor very closely matches a part of the deduced sequence of the v-erb-B transforming protein of avian erythroblastosis virus (AEV).
Journal ArticleDOI
Signaling by distinct classes of phosphoinositide 3-kinases
TL;DR: Different PI3K isoforms generate specific lipids that bind to FYVE and pleckstrin homology domains in a variety of proteins, affecting their localization, conformation, and activities.
Journal ArticleDOI
Autophosphorylation sites on the epidermal growth factor receptor.
TL;DR: It is reported here that three tyrosine sites near the C-terminus are phosphorylated in vitro in the human EGF receptor, and this site is absent in the v-erb-B protein of avian erythroblastosis virus (AEV), which may influence tyosine kinase activity.
Journal ArticleDOI
Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase.
Kamran Salim,M J Bottomley,E Querfurth,Marketa Zvelebil,Ivan Gout,R Scaife,Robert L. Margolis,R Gigg,C. I. E. Smith,Paul C. Driscoll,Mike Waterfield,George Panayotou +11 more
TL;DR: A biosensor‐based assay was used here to probe interactions between PH domains and unilamellar liposomes containing different phospholipids and to demonstrate specificity for distinct phosphoinositides.
Journal ArticleDOI
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Florence I. Raynaud,Suzanne A. Eccles,Paul A. Clarke,Angela Hayes,Bernard Nutley,Sonia Alix,Alan T. Henley,Francesca Di-Stefano,Zahida Ahmad,Sandrine Guillard,Lynn Bjerke,Lloyd R. Kelland,Melanie Valenti,Lisa Patterson,Sharon Gowan,Alexis De Haven Brandon,Masahiko Hayakawa,Hiroyuki Kaizawa,Tomonubu Koizumi,Takahide Ohishi,Sonal Patel,Nahid Saghir,Peter J. Parker,Mike Waterfield,Paul Workman +24 more
TL;DR: Despite its rapid in vivo metabolism, PI103 is a valuable tool compound for exploring the biological function of class I PI3K and importantly represents a lead for further optimization of this novel class of targeted molecular cancer therapeutic.